Literature DB >> 6807598

The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

A N Kotake, D A Schoeller, G H Lambert, A L Baker, D D Schaffer, H Josephs.   

Abstract

The optimal conditions for performing the caffeine CO2 breath test (CBT) were investigated in smokers and nonsmokers. Caffeine labeled with 13C or 14C in all three (1, 3, and 7) methyl groups or specifically in the 1-, 3-, or 7-methyl groups were orally administered to healthy adults and the expiration of labeled CO2 was measured for 8 or 24 hr. The absolute rate of labeled CO2 excretion from trilabeled caffeine was proportional to the dose up to 3 mg/kg in all subjects. In smokers, the rate of labeled CO2 excretion averaged twice that in nonsmokers at all doses. A correlation was observed between the 2-hr cumulative CO2 excretion from trilabeled caffeine and the apparent oral metabolic clearance rate (MCR) of caffeine (R = 0.90). Monolabeled CBTs in smokers and nonsmokers demonstrated that 80% +/- 4% of labeled CO2 expired in the breath during the first 2 hr of a trilabeled CBT was derived from the 3 position; at 6 to 8 hr equal amounts were derived from the 3 and 7 positions. Little N-demethylation was observed from the 1 position at any time during the 8-hr test. The results indicate that the 2-hr cumulative excretion of labeled CO2 could be used to accurately predict the metabolic clearance rate of caffeine is the best CBT parameter for detecting the effect of smoking on caffeine N-demethylation. The data suggest that the primary routes of caffeine metabolism are 3-N-demethylation and ring hydroxylation and confirm that caffeine metabolites are N-demethylated primarily in the 3 and 7 positions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807598     DOI: 10.1038/clpt.1982.157

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Authors:  M A Butler; M Iwasaki; F P Guengerich; F F Kadlubar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

5.  Accumulation of caffeine in healthy volunteers treated with furafylline.

Authors:  E Tarrus; J Cami; D J Roberts; R G Spickett; E Celdran; J Segura
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

6.  Enhanced drug metabolism in young children with cystic fibrosis.

Authors:  A C Parker; P Pritchard; T Preston; R L Smyth; I Choonara
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

Review 7.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

8.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

9.  Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.

Authors:  R J Fontana; T M deVries; T F Woolf; M J Knapp; A S Brown; L S Kaminsky; B K Tang; N L Foster; R R Brown; P B Watkins
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

10.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

Authors:  D Sesardic; A R Boobis; B P Murray; S Murray; J Segura; R de la Torre; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.